OBJECTIVES: Precise characterization of cognitive outcomes and factors that contribute to cognitive variability will enable better understanding of disease progression and treatment effects in mucopolysaccharidosis type I (MPS I). We examined the effects on cognition of phenotype, genotype, age at evaluation and first treatment, and somatic disease burden. METHODS: Sixty patients with severe MPS IH (Hurler syndrome treated with hematopoietic cell transplant and 29 with attenuated MPS I treated with enzyme replacement therapy), were studied with IQ measures, medical history, genotypes. Sixty-seven patients had volumetric MRI. Subjects were grouped by age and phenotype and MRI and compared to 96 normal controls. RESULTS: Prior to hematopoietic cell transplant, MPS IH patients were all cognitively average, but post-transplant, 59% were below average, but stable. Genotype and age at HCT were associated with cognitive ability. In attenuated MPS I, 40% were below average with genotype and somatic disease burden predicting their cognitive ability. White matter volumes were associated with IQ for controls, but not for MPS I. Gray matter volumes were positively associated with IQ in controls and attenuated MPS I patients, but negatively associated in MPS IH. CONCLUSIONS: Cognitive impairment, a major difficulty for many MPS I patients, is associated with genotype, age at treatment and somatic disease burden. IQ association with white matter differed from controls. Many attenuated MPS patients have significant physical and/or cognitive problems and receive insufficient support services. Results provide direction for future clinical trials and better disease management.
OBJECTIVES: Precise characterization of cognitive outcomes and factors that contribute to cognitive variability will enable better understanding of disease progression and treatment effects in mucopolysaccharidosis type I (MPS I). We examined the effects on cognition of phenotype, genotype, age at evaluation and first treatment, and somatic disease burden. METHODS: Sixty patients with severe MPS IH (Hurler syndrome treated with hematopoietic cell transplant and 29 with attenuated MPS I treated with enzyme replacement therapy), were studied with IQ measures, medical history, genotypes. Sixty-seven patients had volumetric MRI. Subjects were grouped by age and phenotype and MRI and compared to 96 normal controls. RESULTS: Prior to hematopoietic cell transplant, MPS IHpatients were all cognitively average, but post-transplant, 59% were below average, but stable. Genotype and age at HCT were associated with cognitive ability. In attenuated MPS I, 40% were below average with genotype and somatic disease burden predicting their cognitive ability. White matter volumes were associated with IQ for controls, but not for MPS I. Gray matter volumes were positively associated with IQ in controls and attenuated MPS Ipatients, but negatively associated in MPS IH. CONCLUSIONS:Cognitive impairment, a major difficulty for many MPS Ipatients, is associated with genotype, age at treatment and somatic disease burden. IQ association with white matter differed from controls. Many attenuated MPSpatients have significant physical and/or cognitive problems and receive insufficient support services. Results provide direction for future clinical trials and better disease management.
Authors: Julie B Eisengart; Kyle D Rudser; Jakub Tolar; Paul J Orchard; Teresa Kivisto; Richard S Ziegler; Chester B Whitley; Elsa G Shapiro Journal: J Pediatr Date: 2012-09-10 Impact factor: 4.406
Authors: Charles H Vite; Igor Nestrasil; Anton Mlikotic; Jackie K Jens; Elizabeth M Snella; William Gross; Elsa G Shapiro; Victor Kovac; James M Provenzale; Steven Chen; Steven Q Le; Shih-hsin Kan; Shida Banakar; Raymond Y Wang; Mark E Haskins; N Matthew Ellinwood; Patricia I Dickson Journal: Comp Med Date: 2013-04 Impact factor: 0.982
Authors: Holly R Martin; Michele D Poe; Debra Reinhartsen; Rebecca E Pretzel; Jackson Roush; Angela Rosenberg; Stacey C Dusing; Maria L Escolar Journal: Acta Paediatr Date: 2008-04 Impact factor: 2.299
Authors: G Souillet; N Guffon; I Maire; M Pujol; P Taylor; F Sevin; N Bleyzac; C Mulier; A Durin; K Kebaili; C Galambrun; Y Bertrand; R Froissart; C Dorche; L Gebuhrer; C Garin; J Berard; P Guibaud Journal: Bone Marrow Transplant Date: 2003-06 Impact factor: 5.483
Authors: Moin U Vera; Steven Q Le; Alla Victoroff; Merry B Passage; Jillian R Brown; Brett E Crawford; Lynda E Polgreen; Agnes H Chen; Patricia I Dickson Journal: Mol Genet Metab Date: 2019-09-11 Impact factor: 4.797
Authors: Victor Kovac; Elsa G Shapiro; Kyle D Rudser; Bryon A Mueller; Julie B Eisengart; Kathleen A Delaney; Alia Ahmed; Kelly E King; Brianna D Yund; Morton J Cowan; Julian Raiman; Eva G Mamak; Paul R Harmatz; Suma P Shankar; Nadia Ali; Stephanie R Cagle; Jeffrey R Wozniak; Kelvin O Lim; Paul J Orchard; Chester B Whitley; Igor Nestrasil Journal: Mol Genet Metab Date: 2022-01-07 Impact factor: 4.797
Authors: Alia Ahmed; Kyle Rudser; Kelly E King; Julie B Eisengart; Paul J Orchard; Elsa Shapiro; Chester B Whitley Journal: Mol Genet Metab Date: 2022-03-10 Impact factor: 4.204
Authors: Agnes H Chen; Paul Harmatz; Igor Nestrasil; Julie B Eisengart; Kelly E King; Kyle Rudser; Alexander M Kaizer; Alena Svatkova; Amy Wakumoto; Steven Q Le; Jacqueline Madden; Sarah Young; Haoyue Zhang; Lynda E Polgreen; Patricia I Dickson Journal: Mol Genet Metab Date: 2019-11-30 Impact factor: 4.797
Authors: Steven Q Le; Igor Nestrasil; Shih-Hsin Kan; Martin Egeland; Jonathan D Cooper; David Elashoff; Rong Guo; Jakub Tolar; Jennifer K Yee; Patricia I Dickson Journal: Lipids Date: 2020-06-14 Impact factor: 1.880
Authors: Kelly E King; Kyle D Rudser; Igor Nestrasil; Victor Kovac; Kathleen A Delaney; Jeffrey R Wozniak; Bryon A Mueller; Kelvin O Lim; Julie B Eisengart; Eva G Mamak; Julian Raiman; Nadia Ali; Stephanie Cagle; Paul Harmatz; Chester B Whitley; Elsa G Shapiro Journal: Neurology Date: 2019-04-12 Impact factor: 9.910